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ORIGINAL ARTICLE – BONE AND SOFT TISSUE SARCOMAS
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ABSTRACT
Background. Nearly half of soft-tissue sarcoma (STS)
patients are over the age of 65, and the behavior of cancer
in these elderly patients is poorly understood. The aim of
this study was to assess the impact of age, sarcoma histo-
type, grade, stage, and treatment modalities on survival of
extremity STS (ESTS) patients.
Methods. Patients C18 years diagnosed with ESTS
between 1989 and 2008 were selected from the Netherlands
Cancer Registry. Survival rates and patient and treatment
characteristics were analyzed for all patients. Relative sur-
vival and relative excess risk of death were estimated for
young (\65 years) and older ([65 years) patients.
Results. Overall, 3066 patients were included in this
study. Histotype was different between young (\65 years)
and elderly ([65 years) patients (p\ 0.001). Patients over
the age of 65 were more often diagnosed with high-stage
ESTS and an increasing proportion of high-grade ESTS
(p\ 0.001). The proportion of patients who received no
treatment increased with age, and the elderly received fewer
combined-modality treatments. Age was significantly
associated with relative 5-year survival [72.7 % for younger
patients and 43.8 % for the oldest elderly ([85 years)]. In
multivariable analysis, age still remained a significant
prognostic factor.
Conclusions. Different distribution of sarcoma histotypes,
more high-stage and high-grade sarcomas at diagnosis, less
aggressive treatment, and worse survival rates emphasize
the need for optimizing sarcoma research and care of the
elderly.
Soft-tissue sarcomas (STS) are relatively rare tumors
and account for 1 % of all cancers in adults.1 The overall
incidence of STS in the Netherlands is 3.2 per 100,000
(European Standardized Rate 2015).2 There has been a
slight increase in the incidence of STS in men.2 Nearly
50 % of the diagnosed patients are over 65 years of age.3
50–60 % of STS are localized in the extremities. The
most common sarcoma histotypes are pleomorphic undif-
ferentiated sarcoma (malignant fibrous histiocytoma),
liposarcoma, leiomyosarcoma, and fibrosarcoma.3,4
Important prognostic factors for STS are primary site,
tumor size, histotype, grade, and stage at presentation.4
Age at presentation determines survival in several distinct
STS histotypes, although the exact cutoff for older age
varies in the studies from 45 to 65 years.5–10
The behavior of cancer in elderly patients is poorly
understood.11,12 There is a widespread misconception that
the elderly are poorly tolerant of chemotherapy and
radiotherapy.11,12 In daily clinical practice, elderly patients
may be undertreated compared to young or middle-aged
STS patients, and this may influence their prognosis.3,13–15
Moreover, elderly patients are generally underrepresented
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or excluded in cancer trials, which compromises our
knowledge of the effectiveness of sarcoma treatment for
this age group.16 For extremity STS (ESTS), there is a
well-defined role for surgery and radiotherapy.17 In ESTS
removed with narrow margins or microscopically (R1) or
macroscopically (R2) positive resection margins, 50–
70 Gy of external-beam radiotherapy is indicated.18,19
The negative impact of older age on sarcoma care and
mortality has been discussed in previous literature. In this
study, we focus on ESTS patients. The goal of the study
was to assess impact of age on relative survival of adult
ESTS patients diagnosed in the Netherlands. Our hypoth-
esis was that older patients were diagnosed at higher stage,
underwent less aggressive treatment, and had lower sur-
vival rates compared to younger patients.
METHODS
Patients (age 18 and older) diagnosed with ESTS as first
primary malignancy in the period 1989–2008 were selected
from the Netherlands Cancer Registry (NCR). Patients with
Kaposi sarcoma, dermatofibrosarcoma protuberans, Ewing
sarcoma, and a two rare sarcomas (alveolar soft part sar-
coma and clear cell sarcoma) were excluded
(Supplementary Table S1). There were no other exclusion
criteria (population-based dataset). PALGA (Pathologisch-
Anatomisch Landelijk Geautomatiseerd Archief), a
nationwide network and registry of histopathology and
cytopathology diagnosis in the Netherlands, regularly
submits reports of all diagnosed malignancies to the cancer
registries.20 The national hospital discharge data bank,
which receives discharge diagnoses of admitted patients
from all Dutch hospitals, completed case ascertainment, so
that all cancer patients are included. After notification,
trained registry personnel collected data on diagnosis,
stage, and treatment from the medical records, including
pathology and surgery reports, using the registration and
coding manual of the NCR for all items. Treatment was
coded in sequence of administration and could consist of
no treatment, surgery, radiotherapy, or chemotherapy as the
only therapy, or a combination (surgery and chemotherapy,
surgery and radiotherapy, or surgery and radiotherapy and
chemotherapy). Stage was assigned according to the
American Joint Committee on Cancer and grade according
to the FNCLCC (Fe´de´ration Nationale des Centres de Lutte
Contre le Cancer).21,22 Survival status (dead or alive) was
established either directly from the patient’s medical record
or through linkage of cancer registry data with the
municipal population registries, which recorded informa-
tion on their inhabitants’ survival status (deceased or alive).
We used the World Health Organization (WHO)
Classification of Soft Tissue Sarcoma for histopathologic
classification of sarcoma histotypes.1 If necessary, STS
were reclassified according to the most recent WHO clas-
sification (2013) (Supplementary Table S1).
Differences in stage at diagnosis, sarcoma histotype,
tumor grade, and treatment regimens were compared
between young and elderly sarcoma patients. Age was
categorized in the following groups: patients \65 and
elderly patients[65 years, further subdivided into 5-year
cohorts: 65–69, 70–74, 75–79, 80–84, and 85? years.
Stage at diagnosis was compared according to age cate-
gories. Treatment was categorized into no treatment,
monotherapy (surgery, radiotherapy, chemotherapy), and
combinations thereof (surgery and chemotherapy, sur-
gery and radiotherapy or surgery, radiotherapy and
chemotherapy). Relative survival was calculated as cause
of death was not known for these patients. Relative sur-
vival was calculated as the ratio of the survival observed
among the ESTS patients and the survival that would
have been expected based on the corresponding (age, sex,
and year) general population. Relative excess risk (RER)
of death was estimated using a multivariable generalized
linear model with a Poisson error structure, based on
collapsed relative survival data, using exact survival
times. Survival time was calculated from the date of
diagnosis and ended at the date of death, date of last
contact, or date of most recent linkage with the municipal
population registries, whichever came first. Relative
mortality (as a result of ESTS) was calculated by the
following equation: [(observed deaths - expected
deaths)/observed deaths]. National life tables were used
to estimate expected survival. Stata/SE 12.0 software
(StataCorp, College Station, TX) was used to perform
statistical analyses.
RESULTS
As shown in Table 1, 3066 patients were included in this
study. At first diagnosis, nearly 40 % of patients were aged
65 years or older, two-thirds (69 %) had high-grade sar-
comas, and 71 % were diagnosed with stage I or II disease.
As shown in Table 1, there were significant differences in
distribution of sarcoma histotypes in young (\65 years)
versus elderly ([65 years) patients (p\ 0.001). Using
65 years of age as the cutoff value, myxoid and round cell
liposarcoma were diagnosed more often in younger
patients (p\ 0.0001), whereas pleomorphic undifferenti-
ated sarcoma was recorded more often in the elderly
(p\ 0.0001). Leiomyosarcoma was predominantly diag-
nosed in the 70–74 age group (p\ 0.001). Elderly patients
presented with high-grade disease more often, ranging
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from 66 % high-grade disease in patients younger than 65–
81 % in the 85? age group (p\ 0.001).
Stage at diagnosis was different between age categories
(p\ 0.001, Fig. 1). The relative proportion of stage I
disease diminished from 38 % in patients \65 years to
27 % for the 85? patients. High-stage disease (stages III
and IV) was more prominent among patients [65 years:
34 % compared to 26 % in patients younger than 65.
As shown in Table 2, the proportion of patients who
received no treatment was higher among patients
[65 years and particularly patients older than 80. Overall,
for patients over the age of 80 years (n = 371), 14.8 %
(n = 55) received no treatment compared to 2.7 % of
patients \65 (p\ 0.001). Surgery as sole treatment was
administered more often to the elderly (ranging from 42 %
in patients \65 years to 53 % in patients 85? years;
p = 0.002). A combination of surgery and radiotherapy
was provided less often to the elderly, particularly patients
85? years (40 % of patients younger than 65 compared to
27 % of the 85? patients; p = 0.004).
Mean follow-up time was 6.2 years with a median of 4.2
(range 0–21) years. Patients younger than 65 had a 5-year
relative survival (all stages) of 72.7 % (95 % confidence
interval 70.4–74.8). For patients[65 years the 5-year rel-
ative survival was significantly worse, decreasing with age
to 43.8 % (95 % confidence interval 28.3–62.3) for the
85? patients. Stratified for stage and age, the p value for
trend (age) was p = 0.01 for stage I, p\ 0.001 for stage II,
p = 0.0001 for stage III, and p = 0.02 for stage IV,
respectively (Fig. 2). When adjusted for sex, year, sarcoma
histotype, grade, and treatment in multivariable analysis,
significant differences between the age groups remained
(stage I: p = 0.02, stage II: p = 0.0002, stage III:
p = 0.0001, stage IV: p = 0.028). The results were con-
firmed after analyzing age as a continuous variable in the
multivariable models: in stage I the RER was 1.02 (1.01–
1.04) with a p value of 0.002, for stage II RER 1.02 (1.01–
1.03), p\ 0.001, for stage III RER 1.02 (1.01–1.02),
p = 0.001, and for stage IV RER 1.01 (1.00–1.02),
p = 0.01. Figure 3 shows that the estimated deaths
(equation [(observed deaths - expected deaths)/observed
deaths]) due to sarcoma after 10 years of follow-up rapidly
decreases among the elderly, although the proportion does
not decrease below 50 % of all deaths.
DISCUSSION
Because the elderly population is growing fast and the
incidence of STS increases with age, elderly cancer care
has become a growing challenge to the world health care
TABLE 1 Characteristics of population by age category
Characteristic Variable Age p*
\65 65–69 70–74 75–79 80–84 85?
Sex Male 1009 (54.0) 145 (50.5) 142 (52.2) 148 (55.6) 109 (53.4) 92 (55.1) 0.8
Female 861 (46.0) 142 (49.5) 130 (47.8) 118 (44.4) 95 (46.6) 75 (44.9)
Year 1989–1993 448 (24.0) 47 (16.4) 69 (25.4) 55 (20.7) 49 (24.0) 34 (20.4) 0.2
1994–1998 416 (22.3) 77 (26.8) 71 (26.1) 58 (21.8) 54 (26.5) 36 (21.5)
1999–2003 474 (25.3) 72 (25.1) 68 (25.0) 68 (25.6) 51 (25.0) 45 (27.0)
2004–2008 532 (28.4) 91 (31.7) 64 (23.5) 85 (31.9) 50 (24.5) 52 (31.1)
Grade Low grade 636 (34.0) 77 (26.8) 70 (25.7) 61 (22.9) 46 (22.6) 32 (19.2) \0.001
High grade 1234 (66.0) 210 (73.2) 202 (74.3) 205 (77.1) 158 (77.4) 135 (80.8)
Sarcoma Dedifferentiated liposarcoma 8 (0.4) 3 (1.1) 1 (0.4) 4 (1.5) 3 (1.5) 3 (1.8) 0.08
Myxoid and round cell liposarcoma 335 (17.9) 17 (5.9) 17 (6.3) 9 (3.4) 4 (2.0) 7 (4.2) \0.001
Pleomorphic liposarcoma 53 (2.8) 7 (2.4) 9 (3.3) 5 (1.9) 8 (3.9) 5 (3.0) 0.8
Mixed-type liposarcoma 22 (1.2) 2 (0.7) 1 (0.4) 3 (1.1) 1 (0.5) 1 (0.6) 0.7
Fibrosarcoma 194 (10.4) 37 (12.9) 24 (8.8) 32 (12.0) 24 (11.8) 19 (11.4) 0.6
Pleomorphic undifferentiated sarcoma 521 (27.9) 113 (39.4) 114 (41.9) 121 (45.5) 101 (49.5) 85 (50.9) \0.001
Leiomyosarcoma 339 (18.1) 78 (27.2) 80 (29.4) 74 (27.8) 46 (22.6) 27 (16.2) \0.001
Rhabdomyosarcoma 55 (2.9) 8 (2.8) 4 (1.5) 3 (1.1) 8 (3.9) 6 (3.6) 0.3
Angiosarcoma 29 (1.6) 6 (2.1) 4 (1.5) 4 (1.5) 5 (2.4) 9 (5.4) 0.002
Synovial sarcoma 228 (12.2) 10 (3.5) 14 (5.1) 7 (2.6) 2 (1.0) 1 (0.6) \0.001
Malignant peripheral nerve sheath tumor 86 (4.6) 6 (2.1) 4 (1.5) 4 (1.5) 2 (1.0) 4 (2.4) 0.002
Overall \0.001**
* p value (v2) for differences in distribution across age categories
** Overall difference in sarcoma distribution across age categories
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systems.23 In keeping with most other series, we found
worse survival outcomes among elderly ESTS
patients.24–26 Differences in presentation and treatment
have often been mentioned as possible explanations for this
inferior prognosis.10,25–28
Part of the reason older patients do worse is that they
often present with larger and higher-grade tumors.23,26,27
This increased rate of high-grade tumors may reflect a
different tumor biology and more genetic alterations and
molecular aberrations in the older population.29 Age can
also be associated with a decline in anti-tumor-cell-medi-
ated immunity.30
Concerning sarcoma histotype, more pleomorphic
undifferentiated sarcomas are diagnosed in the elderly,
which are known to have a relatively adverse prognosis.25
Histopathologic classification of soft tissue sarcoma has
become more accurate over the past 10 years due to
advances in immunohistochemistry (newly developed
antibodies) and molecular biology (FISH and PCR
detecting newly discovered gene translocations which are
more or less histotype specific). Because our study inclu-
ded cases studied between 1989 and 2008, this may have
led to an overrepresentation of the percentage of pleo-
morphic undifferentiated sarcomas, for instance. For
prognosis, treatment, or response to treatment, molecular
characterization already has clinical implications for some
subtypes of sarcoma, and new targets for therapy are
increasingly being revealed.31,32
In this series, elderly patients had less stage I disease at
presentation. This may be a function of late presentation,
often seen in elderly patients with malignancy.27 However,
after stratifying for stages, there are still significant dif-
ferences in relative survival between young and elderly
ESTS patients. This survival difference was found mainly
in stage II and III ESTS patients. A possible explanation
might be that less extensive treatment regimens often
suffice in patients with stage I disease, so age will not be
the reason to withhold any patient from optimal treatment.
For stage IV disease, we know that overall prognosis is
poor for all patients, regardless of the extent of treatment.
This leads to the speculation that suboptimal treatment in
the elderly might contribute to worse survival rates in
stage II and III ESTS patients. A former study from the
cancer registry in the northern part of the Netherlands
showed that referral to a specialized center declined in a
linear fashion with increased age, which might explain
this possible suboptimal treatment of elderly patients.13
Postgraduate medical training of general practitioners,
nursing home physicians, and geriatricians in the differ-
ential diagnosis of soft-tissue masses might contribute to
early and adequate referral.
The principles of treatment for elderly patients are
similar to those for younger patients and those described in
our national guidelines.33 For most ESTS, a combined
treatment modality is assumed to be the optimal therapy
and will be offered to every patient fit enough to undergo
this treatment.15
The mainstay of ESTS treatment is surgery.34 In a
proportion of elderly patients, single treatment (e.g. radical
surgery) is the best option, even if this treatment is sub-
optimal with respect to local or systemic control of
sarcoma.34 Surgeons might be reluctant to perform, or
38
33
28 29 27 26
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<65 65-69 70-74 75-79 80-84 85 and older
Stage I Stage II Stage III Stage IV
FIG. 1 Stage at diagnosis according to
age group
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TABLE 2 Treatment for extremity soft tissue sarcoma patients
Treatment Age n (%) OR (95 % CI) p Adjusted OR (95 % CI) p*
No treatment \0.001 \0.001
\65 50 (2.7) 1.0 (ref) 1.0 (ref)
65–69 13 (4.5) 1.7 (0.9–3.2) 1.6 (0.8–3.1)
70–74 24 (8.8) 3.5 (2.1–5.8) 3.2 (1.8–5.6)
75–79 15 (5.6) 2.2 (1.2–3.9) 1.7 (0.9–3.3)
80–84 28 (13.7) 5.8 (3.6–9.4) 5.6 (3.2–9.6)
85? 27 (16.2) 7.0 (4.3–11.6) 8.3 (4.7–14.6)
Surgery (monotherapy) 0.002 0.0003
\65 787 (42.1) 1.0 (ref) 1.0 (ref)
65–69 105 (36.6) 0.8 (0.6–1.0) 0.8 (0.6–1.0)
70–74 93 (34.2) 0.7 (0.5–0.9) 0.7 (0.5–0.9)
75–79 121 (45.5) 1.1 (0.9–1.5) 1.2 (0.9–1.6)
80–84 82 (40.2) 0.9 (0.7–1.2) 0.9 (0.7–1.3)
85? 88 (52.7) 1.5 (1.1–2.1) 1.7 (1.2–2.3)
Radiotherapy (monotherapy) \0.001 0.0003
\65 13 (0.7) 1.0 (ref) 1.0 (ref)
65–69 4 (1.4) 2.0 (0.7–6.2) 2.0 (0.6–6.2)
70–74 5 (1.8) 2.7 (0.9–7.6) 2.4 (0.8–7.0)
75–79 12 (4.5) 6.7 (3.0–15.0) 6.3 (2.7–14.8)
80–84 9 (4.4) 6.6 (2.8–15.6) 6.1 (2.4–15.1)
85? 3 (1.8) 2.6 (0.7–9.3) 2.4 (0.7–9.0)
Chemotherapy (monotherapy) 0.4 0.2
\65 74 (4.0) 1.0 (ref) 1.0 (ref)
65–69 13 (4.5) 1.2 (0.6–2.1) 1.1 (0.6–2.2)
70–74 14 (5.2) 1.3 (0.7–2.4) 1.2 (0.7–2.4)
75–79 7 (2.6) 0.7 (0.3–1.4) 0.5 (0.2–1.2)
80–84 4 (2.0) 0.5 (0.2–1.3) 0.4 (0.1–1.1)
85? 4 (2.4) 0.6 (0.2–1.6) 0.7 (0.2–2.0)
Surgery and chemotherapy 0.06 0.08
\65 96 (5.1) 1.0 (ref) 1.0 (ref)
65–69 16 (5.6) 1.1 (0.6–1.9) 1.1 (0.6–2.0)
70–74 8 (2.9) 0.6 (0.3–1.2) 0.6 (0.3–1.2)
75–79 5 (1.9) 0.4 (0.1–0.9) 0.4 (0.1–0.9)
80–84 6 (2.9) 0.6 (0.2–1.3) 0.5 (0.2–1.3)
85? 0 (0.0) – –
Surgery and radiotherapy 0.004 0.0005
\65 739 (39.5) 1.0 (ref) 1.0 (ref)
65–69 124 (43.2) 1.2 (0.9–1.5) 1.2 (1.0–1.6)
70–74 124 (45.6) 1.3 (1.0–1.6) 1.4 (1.1–1.9)
75–79 102 (38.4) 1.0 (0.7–1.2) 1.0 (0.7–1.3)
80–84 74 (36.3) 0.9 (0.6–1.2) 0.9 (0.7–1.3)
85? 45 (27.0) 0.6 (0.4–0.8) 0.5 (0.4–0.8)
Surgery and radiotherapy and chemotherapy 0.001 0.003
\65 96 (5.1) 1.0 (ref) 1.0 (ref)
65–69 10 (3.5) 0.7 (0.4–1.3) 0.7 (0.3–1.3)
70–74 4 (1.5) 0.3 (0.1–0.8) 0.3 (0.1–0.8)
75–79 4 (1.5) 0.3 (0.1–0.8) 0.3 (0.1–0.8)
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patients to accept, morbid surgeries with increasing patient
age, leading to inferior surgical treatment.26,35 In our ser-
ies, almost 90 % of patients underwent any form of
surgery. In the cohort of patients[75 years, this proportion
was still 83 %. Lahat and colleagues have already advo-
cated radical surgery in the elderly, as properly selected
patients can safely undergo extensive STS resections. Their
study showed that even in the group of patients aged C75,
more than half survived 5 years or more when treated with
aggressive surgery.23 However, a large but highly select
group of patients was investigated in this series. Patients
with incomplete resection, insufficient follow-up, and
nonspecific pathologic diagnoses were excluded; this might
be a patient group with unfavorable prognostic character-
istics but one that could actually benefit from better
staging, referral, or customized treatment. Buchner et al.
also justify extensive surgery in bone and soft tissue sar-
coma patients aged[70. They state, however, that general
condition and comorbidity should be given due
consideration.36 Fitness for general anesthesia should be
the determinant for suitability for surgery in elderly
patients rather than chronological age.37
Patients with gross disease will benefit from preopera-
tive radiotherapy, although this is accompanied with
increased treatment-related morbidity such as wound-
healing disturbances and those with less than adequate
margins after surgery from adjuvant radiotherapy.34,38 In
particular, surgery combined with radiotherapy was less
often administered in the 85? group compared to the other
age groups. Physicians can be cautious in offering (neo-)
adjuvant radiotherapy to elderly patients, especially if there
is an expected benefit in the longer term while the overall
life expectancy might be short. Furthermore, logistical
problems and patient preferences are often the reason that
elderly patients refuse long courses of external radiation.27
Horton et al. showed that patients aged C70 with high-
grade ESTS were less likely to receive radiotherapy, and
furthermore that not receiving radiotherapy was associated
TABLE 2 continued
Treatment Age n (%) OR (95 % CI) p Adjusted OR (95 % CI) p*
80–84 1 (0.5) 0.1 (0.01–0.7) 0.1 (0.01–0.7)
85? 0 (0.0) – –
Chemotherapy and radiotherapy: 15 patients\65 years and two patients aged 65–69 years
Ref reference category




























































































Stage I Stage II Stage III Stage IV Overall
FIG. 2 Relative survival for sarcoma patients according to patient age and disease stage
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with mortality and disease-specific death.39 In the popula-
tion-based study of Al-Refaie et al., sarcoma-directed
surgery and administration of adjuvant radiotherapy after
limb-sparing surgery for T2 or high-grade tumors were also
decreased for ESTS patients aged C85.28
The role of chemotherapy in the treatment of ESTS
remains controversial. Chemotherapy turns out to be inef-
fective in the majority of the ESTS, and toxicity may be
significant.34,40,41 As expected, administration of
chemotherapy with or without surgery and/or radiotherapy
declines with age in our series. There is, however, a
widespread misconception that the elderly are always
poorly tolerant of chemotherapy.11,42 Most adult cancer
patients can tolerate it with limited impact on indepen-
dence, comorbidity, and quality-of-life levels, although
half of the population experienced severe adverse effects.42
The proportion of patients who received no treatment at
all increased significantly with age. Former studies from
our own center showed that the decision to refrain from
cancer treatment was mostly disease related and was less
often based on poor general health status.15
Strikingly, in contrast to most other types of cancer, and
despite continuous efforts to improve sarcoma treatment,
more individual customized therapy, relatively new treat-
ment modalities (like hyperthermic isolated limb perfusion
for locally advanced STS of the extremity), and better
compliance with guidelines, other series show that survival
rates have not improved over time for all age groups.43
Further research is thus extremely important to discover the
gaps in sarcoma treatment and find areas with room for
improvement.
The results of this study are based on data from a cancer
registry, which was used in order to gain insight into the
disease and discover differences in treatment and survival
for different age groups. Because there are no data on
patient frailty in the cancer registry, we cannot comment on
the just or unjust allocation of treatment. Accurate reports
in the medical records on diagnosis, staging, treatment, and
follow-up details are essential for reliable registration and
analysis. Because the national cancer registry does not
register for comorbidity, type of surgery and/or
chemotherapy, quality of surgery, or hospital-level factors,
a more detailed analysis was not possible.
Elderly patients are also generally underrepresented in
cancer trials, which compromises the generalizability of
the effectiveness of sarcoma treatments to this age group,
and future efforts should identify methods to improve low
accrual rates of the elderly in clinical cancer trials and
should explore other research designs to study the
elderly.16,44
CONCLUSIONS
Studies on STS care in the elderly are extremely
important to gain better insight into treatment and survival
differences; the current norm of individual, customized
sarcoma treatment also applies to elderly ESTS patients.
Different distribution of sarcomas, more high-grade and
high-stage sarcomas, less aggressive treatment, and lower
survival of the elderly emphasize the need for optimizing
sarcoma care that may improve survival rates of elderly
sarcoma patients.
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